John Pierce, MD
Family Medicine · Perrysburg, OHNPI 1598755712
Payments from drug & device makers
Across 145 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$290
- Pfizer$218
- Novartis$182
- Johnson & Johnson$172
- Novo Nordisk$158
- Dexcom, Inc.$128
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $290 |
| Pfizer | 13 | $218 |
| Novartis | 12 | $182 |
| Johnson & Johnson | 10 | $172 |
| Novo Nordisk | 12 | $158 |
| Dexcom, Inc. | 6 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Exact Sciences | 5 | $91 |
| Abbott | 5 | $91 |
| Amgen | 6 | $88 |
| Merck | 6 | $88 |
| AstraZeneca | 6 | $81 |
| Bayer | 5 | $80 |
| Amarin Pharma, Inc. | 5 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Boehringer Ingelheim | 3 | $42 |
| Lilly USA, LLC | 2 | $31 |
| Eisai Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Medline Industries LP | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Si-bone, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Corium, LLC | 1 | $13 |
| GSK | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Biogen | 1 | $11 |
How this compares
$2,296 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 393 | $234,383 |
| OzempicSemaglutide | 198 | $222,130 |
| JardianceEmpagliflozin | 191 | $197,951 |
| TrulicityDulaglutide | 173 | $197,026 |
| FarxigaDapagliflozin Propanediol | 127 | $112,061 |
| JanuviaSitagliptin Phosphate | 118 | $97,034 |
| Tresiba Flextouch U-200Insulin Degludec | 106 | $96,684 |
| HumiraAdalimumab | 13 | $95,925 |
| XareltoRivaroxaban | 99 | $85,486 |
| VraylarCariprazine Hcl | 71 | $83,250 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $61,206 |
| RexultiBrexpiprazole | 44 | $58,928 |
| EntrestoSacubitril/Valsartan | 103 | $42,524 |
| InvokanaCanagliflozin | 29 | $33,265 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $32,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Vraylar, Creon, Qulipta, Linzess | $290 | $236,159138 claims |
| PfizerEliquis | $218 | $234,383393 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $229,052228 claims |
| Novo NordiskOzempic | $158 | $222,130198 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $218,509190 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $81 | $141,953212 claims |
| Johnson & JohnsonXarelto, Invokana | $172 | $118,751128 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $12 | $103,345153 claims |
| MerckJanuvia | $88 | $97,034118 claims |
| NovartisEntresto | $182 | $42,524103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Perrysburg
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.